PALATIN TECHNOLOGIES INC

PTN

Held by 3 specialist biotech funds

High Convergence

Share on X

Fund Holdings

3 fund convergence

Driehaus Capital RA Capital Management Perceptive Advisors

Catalysts

No catalysts tracked.

Position Details

Driehaus CapitalNEWFeb 17, 2026

Shares: 166,713Value: $2.6M

Driehaus's $2.6M entry into PTN suggests conviction in Palatin's lead program PT-141 (bremelanotide) for hypoactive sexual desire disorder (HSDD), which received FDA approval in June 2019 and is generating early commercial traction. The position timing may reflect confidence in upcoming quarterly revenue reports or potential label expansion catalysts, particularly given Palatin's historically volatile stock and the growth-oriented fund's typical thesis around undervalued biotech commercialization stories.

RA Capital ManagementNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

SION3 funds NUVL3 funds IVVD3 funds PEPG3 funds ASND3 funds EWTX3 funds SYRE3 funds SEPN

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

# Signal Note: RA Capital Entry into PTN RA Capital's $1.1M initiation in Palatin suggests conviction in the company's lead candidate flbrussoretide (PAL-9045), a melanocortin-4 receptor agonist for obesity currently in Phase 2b development. The timing likely reflects confidence in near-term data readouts expected in 2024-2025, positioning PTN to capitalize on the competitive GLP-1 alternative landscape if efficacy/safety warrant advancement. Kolchinsky's involvement typically signals focus on undervalued science rather than hype, implying the market may be underpricing PTN's clinical potential relative to the obesity therapeutic opportunity.